Bioprospecting and Biodiversity Conservation: What Happens When Discoveries are Made?

There has been extensive debate over whether private-sector bioprospecting for pharmaceutical compounds creates significant incentives for biodiversity conservation. We offer a case study of the discovery and commercial development of the anti-cancer drug taxol from the Pacific yew tree, highlighting neglected issues in the debate over bioprospecting and conservation incentives.